eicosapentaenoic acid ethyl ester has been researched along with 2019 Novel Coronavirus Disease in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 3 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jia, X | 1 |
| Al Rifai, M | 1 |
| Hussain, A | 1 |
| Martin, S | 1 |
| Agarwala, A | 1 |
| Virani, SS | 1 |
| Ambrosy, AP | 1 |
| Malik, UI | 1 |
| Thomas, RC | 1 |
| Parikh, RV | 1 |
| Tan, TC | 1 |
| Goh, CH | 1 |
| Selby, VN | 1 |
| Solomon, MD | 1 |
| Avula, HR | 1 |
| Fitzpatrick, JK | 1 |
| Skarbinski, J | 1 |
| Philip, S | 1 |
| Granowitz, C | 1 |
| Bhatt, DL | 1 |
| Go, AS | 1 |
| Simopoulos, AP | 1 |
| Serhan, CN | 1 |
| Bazinet, RP | 1 |
1 review available for eicosapentaenoic acid ethyl ester and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Highlights from Studies in Cardiovascular Disease Prevention Presented at the Digital 2020 European Society of Cardiology Congress: Prevention Is Alive and Well.
Topics: Benzhydryl Compounds; Betacoronavirus; Cardiology; Cardiovascular Agents; Cardiovascular Diseases; C | 2020 |
1 trial available for eicosapentaenoic acid ethyl ester and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Rationale and design of the pragmatic randomized trial of icosapent ethyl for high cardiovascular risk adults (MITIGATE).
Topics: Aged; Atherosclerosis; Cardiovascular Diseases; COVID-19; Eicosapentaenoic Acid; Female; Humans; Hyd | 2021 |
1 other study available for eicosapentaenoic acid ethyl ester and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
The need for precision nutrition, genetic variation and resolution in Covid-19 patients.
Topics: COVID-19; Docosahexaenoic Acids; Eicosanoids; Eicosapentaenoic Acid; Fatty Acids, Essential; Fatty A | 2021 |